Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander G G Turpie

Showing results (71-80 of 177) with videos related to

Pageof 18
Sort By:
Vascular Health and Risk Management|June 16, 2012
Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgeryAlexander G G Turpie, André C Schmidt, Reinhold Kreutz, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 19, 2018
Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1Craig I Coleman, Alexander G G Turpie, Thomas J Bunz, et al.
The American Journal of Cardiology|September 23, 2008
Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry)Alex C Spyropoulos, Alexander G G Turpie, Andrew S Dunn, et al.
Clinical Cardiology|September 8, 2020
Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective studyA John Camm, Pierre Amarenco, Sylvia Haas, et al.
Clinical Therapeutics|October 21, 2015
Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014Jeffrey I Weitz, William Semchuk, Alexander G G Turpie, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|July 28, 2018
Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUSA John Camm, Pierre Amarenco, Sylvia Haas, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 14, 2018
Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS studyPierre Amarenco, Sylvia Haas, Susanne Hess, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|June 28, 2024
Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUSPaulus Kirchhof, Sylvia Haas, Pierre Amarenco, et al.
Archives of Internal Medicine|February 16, 2005
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trialNils Kucher, Alain Leizorovicz, Paul T Vaitkus, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 11, 2017
Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS studyA John Camm, Alexander G G Turpie, Susanne Hess, et al.
Pageof 18

Showing results (71-80 of 177) with videos related to

Sort By:
Pageof 18
Vascular Health and Risk Management|June 16, 2012
Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgeryAlexander G G Turpie, André C Schmidt, Reinhold Kreutz, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 19, 2018
Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1Craig I Coleman, Alexander G G Turpie, Thomas J Bunz, et al.
The American Journal of Cardiology|September 23, 2008
Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry)Alex C Spyropoulos, Alexander G G Turpie, Andrew S Dunn, et al.
Clinical Cardiology|September 8, 2020
Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective studyA John Camm, Pierre Amarenco, Sylvia Haas, et al.
Clinical Therapeutics|October 21, 2015
Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014Jeffrey I Weitz, William Semchuk, Alexander G G Turpie, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|July 28, 2018
Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUSA John Camm, Pierre Amarenco, Sylvia Haas, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 14, 2018
Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS studyPierre Amarenco, Sylvia Haas, Susanne Hess, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|June 28, 2024
Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUSPaulus Kirchhof, Sylvia Haas, Pierre Amarenco, et al.
Archives of Internal Medicine|February 16, 2005
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trialNils Kucher, Alain Leizorovicz, Paul T Vaitkus, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 11, 2017
Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS studyA John Camm, Alexander G G Turpie, Susanne Hess, et al.
Pageof 18